The US Food and Drug Administration (FDA) is currently examining reports of side effects, such as hair loss and suicidal thoughts, associated with medications like Ozempic, Mounjaro, and Wegovy.
These drugs belong to a class known as GLP-1 receptor agonists and are approved for the treatment of diabetes or weight loss.
The medications in question include semaglutide (Ozempic, Rybelsus, Wegovy), liraglutide (Saxenda, Victoza), and tirzepatide (Mounjaro, Zepbound). GLP-1 receptor agonists mimic the natural hormone GLP-1, which plays a role in various bodily functions, including slowing down the passage of food through the stomach. US Food and Drug
The FDA is “evaluating the need for regulatory action” after its FDA Adverse Event Reporting System or FAERS received reports of alopecia, or hair loss; aspiration, or accidentally breathing in things like food or liquid; and suicidal ideation in people using these medications.
The FDA is currently evaluating reports of potential side effects, including hair loss and suicidal thoughts, associated with medications like Ozempic, Mounjaro, and Wegovy, which belong to the class of GLP-1 receptor agonists. It’s important to note that the presence of a drug on this list does not necessarily indicate that the FDA has confirmed a causal relationship between the drug and the listed risk. The FDA emphasizes that it identifies potential safety issues, and further investigation is required to establish any causal relationship.
Individuals using these medications are advised to consult with their healthcare provider if they have questions or concerns about potential side effects. The FDA continuously monitors the safety of drugs throughout their life cycle and maintains postmarketing surveillance and risk assessment programs.
Previous research has linked GLP-1 agonists to rare but serious digestive problems, including stomach paralysis, pancreatitis, and bowel obstructions. Some caution has been recommended in specific situations, such as discontinuing the use of GLP-1 agonists a week before surgical procedures to minimize potential gastrointestinal issues during anesthesia.